Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push

Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push

August 31, 2026Posted inBiotechnology

The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline.

Post navigation

Previous Post
ESC26: AstraZeneca’s heart failure drug shows promise in ph. 2 trial
Next Post
Synthetically Engineered Marine Bacteria Could Play Key Role in Decarbonizing the Atmosphere at Industrial Scales synthetically-engineered-marine-bacteria-could-play-key-role-in-decarbonizing-the-atmosphere-at-industrial-scales

Recent Posts

  • FWB-SMOTE Algorithm Outperforms Eleven Benchmarks on Imbalanced Datasets Across Three Classifiers
  • Explainable Deep Learning Model Accurately Detects Industrial Network Cyber Threats
  • Smoothing Methods Enhance Machine Learning State-of-Health Predictions for Lithium-Ion Batteries
  • Forest Conditions Outside National Parks Strongly Influence Bird Presence Within Them
  • Maternal Poor Sleep Quality Linked to Congenital Heart Defects in Offspring

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top